No recent analyst price targets found for CDXC.
Latest News for CDXC
Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces the sale of its ChromaDex Reference Standards business to LGC, as of February 24, 2026, in an all-cash transaction. The divestiture further streamlines Niagen Bioscience's operations, advances the…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CDXC.
U.S. House Trading
No House trades found for CDXC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.